vs

Side-by-side financial comparison of BEASLEY BROADCAST GROUP INC (BBGI) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.

MESA LABORATORIES INC is the larger business by last-quarter revenue ($65.1M vs $53.1M, roughly 1.2× BEASLEY BROADCAST GROUP INC). MESA LABORATORIES INC runs the higher net margin — 5.6% vs -358.4%, a 364.0% gap on every dollar of revenue. On growth, MESA LABORATORIES INC posted the faster year-over-year revenue change (3.6% vs -21.2%). MESA LABORATORIES INC produced more free cash flow last quarter ($18.0M vs $-4.4M). Over the past eight quarters, MESA LABORATORIES INC's revenue compounded faster (5.1% CAGR vs -1.2%).

Beasley Broadcast Group, Inc., based in Naples, Florida, is an owner/operator of radio stations in the United States. As of September 2025, the company owns 54 stations under the Beasley Media Group name.

Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.

BBGI vs MLAB — Head-to-Head

Bigger by revenue
MLAB
MLAB
1.2× larger
MLAB
$65.1M
$53.1M
BBGI
Growing faster (revenue YoY)
MLAB
MLAB
+24.8% gap
MLAB
3.6%
-21.2%
BBGI
Higher net margin
MLAB
MLAB
364.0% more per $
MLAB
5.6%
-358.4%
BBGI
More free cash flow
MLAB
MLAB
$22.4M more FCF
MLAB
$18.0M
$-4.4M
BBGI
Faster 2-yr revenue CAGR
MLAB
MLAB
Annualised
MLAB
5.1%
-1.2%
BBGI

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
BBGI
BBGI
MLAB
MLAB
Revenue
$53.1M
$65.1M
Net Profit
$-190.1M
$3.6M
Gross Margin
64.2%
Operating Margin
-433.6%
12.2%
Net Margin
-358.4%
5.6%
Revenue YoY
-21.2%
3.6%
Net Profit YoY
-9136.7%
316.6%
EPS (diluted)
$-105.71
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBGI
BBGI
MLAB
MLAB
Q4 25
$53.1M
$65.1M
Q3 25
$51.0M
$60.7M
Q2 25
$53.0M
$59.5M
Q1 25
$48.9M
$62.1M
Q4 24
$67.3M
$62.8M
Q3 24
$58.2M
$57.8M
Q2 24
$60.4M
$58.2M
Q1 24
$54.4M
$58.9M
Net Profit
BBGI
BBGI
MLAB
MLAB
Q4 25
$-190.1M
$3.6M
Q3 25
$-3.6M
$2.5M
Q2 25
$-154.2K
$4.7M
Q1 25
$-2.7M
$-7.1M
Q4 24
$-2.1M
$-1.7M
Q3 24
$-3.6M
$3.4M
Q2 24
$-276.0K
$3.4M
Q1 24
$8.0K
$-254.6M
Gross Margin
BBGI
BBGI
MLAB
MLAB
Q4 25
64.2%
Q3 25
61.5%
Q2 25
62.0%
Q1 25
61.8%
Q4 24
63.3%
Q3 24
61.3%
Q2 24
64.0%
Q1 24
62.1%
Operating Margin
BBGI
BBGI
MLAB
MLAB
Q4 25
-433.6%
12.2%
Q3 25
-1.1%
7.8%
Q2 25
5.5%
5.1%
Q1 25
-4.1%
2.4%
Q4 24
11.3%
9.2%
Q3 24
2.1%
6.1%
Q2 24
8.9%
9.6%
Q1 24
-2.0%
-460.6%
Net Margin
BBGI
BBGI
MLAB
MLAB
Q4 25
-358.4%
5.6%
Q3 25
-7.0%
4.1%
Q2 25
-0.3%
8.0%
Q1 25
-5.5%
-11.4%
Q4 24
-3.1%
-2.7%
Q3 24
-6.1%
5.9%
Q2 24
-0.5%
5.8%
Q1 24
0.0%
-432.2%
EPS (diluted)
BBGI
BBGI
MLAB
MLAB
Q4 25
$-105.71
$0.65
Q3 25
$-1.97
$0.45
Q2 25
$-0.09
$0.85
Q1 25
$-1.50
$-1.30
Q4 24
$-1.23
$-0.31
Q3 24
$-2.33
$0.63
Q2 24
$-0.18
$0.62
Q1 24
$0.01
$-47.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBGI
BBGI
MLAB
MLAB
Cash + ST InvestmentsLiquidity on hand
$9.9M
$29.0M
Total DebtLower is stronger
$68.4M
Stockholders' EquityBook value
$-49.3M
$186.7M
Total Assets
$299.3M
$434.8M
Debt / EquityLower = less leverage
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBGI
BBGI
MLAB
MLAB
Q4 25
$9.9M
$29.0M
Q3 25
$14.3M
$20.4M
Q2 25
$13.7M
$21.3M
Q1 25
$12.2M
$27.3M
Q4 24
$13.8M
$27.3M
Q3 24
$27.8M
$24.3M
Q2 24
$33.3M
$28.5M
Q1 24
$27.8M
$28.2M
Total Debt
BBGI
BBGI
MLAB
MLAB
Q4 25
$68.4M
Q3 25
$69.4M
Q2 25
$70.3M
Q1 25
$71.3M
Q4 24
$247.1M
$72.2M
Q3 24
$265.2M
$73.1M
Q2 24
$264.9M
$74.1M
Q1 24
$264.5M
Stockholders' Equity
BBGI
BBGI
MLAB
MLAB
Q4 25
$-49.3M
$186.7M
Q3 25
$141.0M
$178.5M
Q2 25
$144.5M
$172.5M
Q1 25
$144.6M
$159.8M
Q4 24
$147.2M
$155.2M
Q3 24
$145.8M
$161.5M
Q2 24
$149.1M
$150.7M
Q1 24
$149.1M
$145.4M
Total Assets
BBGI
BBGI
MLAB
MLAB
Q4 25
$299.3M
$434.8M
Q3 25
$534.6M
$430.4M
Q2 25
$548.0M
$435.7M
Q1 25
$539.3M
$433.3M
Q4 24
$549.2M
$433.3M
Q3 24
$571.5M
$454.1M
Q2 24
$573.2M
$440.4M
Q1 24
$566.3M
$446.8M
Debt / Equity
BBGI
BBGI
MLAB
MLAB
Q4 25
0.37×
Q3 25
0.39×
Q2 25
0.41×
Q1 25
0.45×
Q4 24
1.68×
0.47×
Q3 24
1.82×
0.45×
Q2 24
1.78×
0.49×
Q1 24
1.77×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBGI
BBGI
MLAB
MLAB
Operating Cash FlowLast quarter
$-3.2M
$18.8M
Free Cash FlowOCF − Capex
$-4.4M
$18.0M
FCF MarginFCF / Revenue
-8.3%
27.7%
Capex IntensityCapex / Revenue
2.3%
1.1%
Cash ConversionOCF / Net Profit
5.17×
TTM Free Cash FlowTrailing 4 quarters
$-13.3M
$37.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBGI
BBGI
MLAB
MLAB
Q4 25
$-3.2M
$18.8M
Q3 25
$-4.9M
$8.2M
Q2 25
$3.1M
$1.9M
Q1 25
$-3.5M
$12.7M
Q4 24
$-1.5M
$18.1M
Q3 24
$-4.8M
$5.3M
Q2 24
$6.6M
$10.7M
Q1 24
$-4.0M
$12.9M
Free Cash Flow
BBGI
BBGI
MLAB
MLAB
Q4 25
$-4.4M
$18.0M
Q3 25
$-7.1M
$7.1M
Q2 25
$2.5M
$884.0K
Q1 25
$-4.3M
$11.9M
Q4 24
$-1.9M
$17.3M
Q3 24
$-5.4M
$3.5M
Q2 24
$5.6M
$9.9M
Q1 24
$-5.0M
$12.3M
FCF Margin
BBGI
BBGI
MLAB
MLAB
Q4 25
-8.3%
27.7%
Q3 25
-14.0%
11.7%
Q2 25
4.7%
1.5%
Q1 25
-8.7%
19.2%
Q4 24
-2.8%
27.6%
Q3 24
-9.3%
6.0%
Q2 24
9.2%
16.9%
Q1 24
-9.2%
21.0%
Capex Intensity
BBGI
BBGI
MLAB
MLAB
Q4 25
2.3%
1.1%
Q3 25
4.4%
1.8%
Q2 25
1.1%
1.7%
Q1 25
1.6%
1.2%
Q4 24
0.6%
1.3%
Q3 24
1.1%
3.1%
Q2 24
1.7%
1.5%
Q1 24
1.7%
0.9%
Cash Conversion
BBGI
BBGI
MLAB
MLAB
Q4 25
5.17×
Q3 25
3.32×
Q2 25
0.40×
Q1 25
Q4 24
Q3 24
1.54×
Q2 24
3.17×
Q1 24
-506.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBGI
BBGI

Audio Advertising$40.5M76%
Digital Advertising$12.6M24%

MLAB
MLAB

Sterilization And Disinfection Control$24.9M38%
Biopharmaceutical Development$14.4M22%
Other$14.1M22%
Clinical Genomics$11.8M18%

Related Comparisons